Health Care and Biotech
Alcidion’s IT Targets Hospital Efficiency
Alcidion is an emerging operator in the field of hospital IT, with technology that can reduce deaths attributable to medical error. The stock price has doubled since it listed on ASX in February this year.
Dec 19 2016
Estia Health Beset By Uncertainty
Estia Health is beset by uncertainty surrounding the sustainability of earnings and this is not expected to moderate in the near term.
Dec 13 2016
Rebound For Sirtex
Michael Gable of Fairmont Equities suggests technically, Sirtex Medical should be set to recover.
Dec 13 2016
Sirtex Reaction Overdone
Increased competition has wedged dose sales for Sirtex Medical but brokers suspect the market’s reaction is overdone.
Dec 12 2016
Previous Stories
API Surprises, But Brokers Non-Enthusiastic
Oct 22 2009
Most Australian stockbrokers simply cannot get excited about Australian Pharmaceutical Industries.
Generic Margins Remain The Issue For Sigma
Sep 15 2009
Brokers were generally nonplussed by the Sigma Pharmaceuticals interim result as margins in the generic business remain a concern and an impediment to group earnings growth.
Primary Refinancing Removes Perceived Overhang
Sep 14 2009
Primary Health Care is to refinance $1.2bn in debt and the move is seen as removing a perceived overhang.
Stockbrokers Cannot Get Excited About Sigma
Sep 08 2009
Sigma Pharmaceuticals has acquired 15 brands plus a manufacturing facility from BMS and announced a rights issue.
Acquisition Growth A Key Variable For Sonic Healthcare
Aug 31 2009
Sonic Healthcare has a significant war chest for acquisitions and this year it might start using it to continue growing the business.
Where’s The Value In CSL?
Aug 20 2009
Some stockbrokers see CSL’s earnings guidance for FY10 as conservative, others argue the stock is not good value.
US Expansion On The Cards For iSOFT
Aug 13 2009
Healthcare IT group iSOFT’s US acquisition could be a beach-head into a market offering significant growth potential.
Primary Health Delivers On Promised Synergies
Aug 12 2009
Primary Health Care posted a profit result brokers viewed as solid.
Chinese Upside To Cochlear’s Numbers?
Jul 24 2009
UBS is the only broker to rate Cochlear a Buy in the FNArena database and it sees upside risk to its forecasts from additional sales in China.
Could CSL Disappoint On Expectations?
Jun 30 2009
Most brokers covering CSL are bullish on the stock, but Morgan Stanley offers some reasons why earnings could fall short of expectations.
